BMRA

Biomerica Inc

2.20

Sep 02 • 3:58 PM ET +0.11 (5.26%)

2.20

Aftermarket • 7:30 PM ET +0.00 (0.00%)

Healthcare Medical Devices USA Nano NASD

Sep 01, 8:25 AMBiomerica reports fiscal 2026 year-end results, with net loss narrowing 24% to $3.8 million and fourth-quarter net sales rising 17% year over year.

Peers: HSCS INBS IVF NXL TNON XAIR AEMD BJDX NUWE VTAK

| Held by: VXF

Index	-
Market Cap	6.80M
Enterprise Value	5.65M
Income	-4.17M
Sales	4.33M
Book/sh	1.09
Cash/sh	0.43
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Mar 17, 1980

P/E	-
Forward P/E	-
PEG	-
P/S	1.57
P/B	2.01
P/C	5.07
P/FCF	-
EV/EBITDA	-
EV/Sales	1.30
Quick Ratio	1.59
Current Ratio	2.64
Debt/Eq	0.06
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.50
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	8.87% -3.30%
Sales past 3/5Y	-34.47% -4.52%
EPS Y/Y TTM	32.96%
Sales Y/Y TTM	-23.81%
EPS Q/Q	10.14%
Sales Q/Q	-11.80%
Earnings	Sep 01 BMO
EPS/Sales Surpr.	- -

Insider Own	32.24%
Insider Trans	29.14%
Inst Own	4.05%
Inst Trans	1.07%
ROA	-68.12%
ROE	-94.32%
ROIC	-125.84%
Gross Margin	4.32%
Oper. Margin	-123.74%
Profit Margin	-96.49%
SMA20	26.38%
SMA50	30.35%
SMA200	3.50%
Trades

Shs Outstand	3.03M
Shs Float	2.09M
Short Float	0.88%
Short Ratio	0.28
Short Interest	0.02M
52W High	3.22 -31.68%
52W Low	1.45 51.72%
Volatility	14.75% 6.37%
ATR (14)	0.14
RSI (14)	73.61
Beta	0.39
Rel Volume	1.12
Avg Volume	64.91K
Volume	72,819

Perf Week	30.19%
Perf Month	43.79%
Perf Quarter	4.27%
Perf Half Y	8.37%
Perf YTD	-12.70%
Perf Year	-26.67%
Perf 3Y	-78.68%
Perf 5Y	-93.98%
Perf 10Y	-90.14%
Recom	1.00
Target Price	6.25
Prev Close	2.09
Price	2.20
Change %	5.26%

Date	Action	Analyst	Rating Change	Price Target Change
May-05-26	Initiated	Citizens	Mkt Outperform	$9
Nov-10-20	Initiated	Colliers Securities	Buy	$13
Jan-04-18	Initiated	B. Riley FBR, Inc.	Buy	$7.50

Sep-01-26 08:19AM	Biomerica Reports Fiscal 2026 Year-End Financial Results (GlobeNewswire)
Aug-27-26 08:19AM	Biomerica Announces $2.23 Million Financing (GlobeNewswire) +24.27%
May-28-26 08:19AM	Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development (GlobeNewswire)
Apr-29-26 08:19AM	Biomerica's inFoods IBS Data Accepted for Presentation at Digestive Disease Week 2026 (GlobeNewswire)
Apr-16-26 08:19AM	Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods IBS, Opening a Scalable Medicare Commercialization Pathway (GlobeNewswire)
08:19AM	Loading…
Apr-14-26 08:19AM	Biomerica Launches inFoods IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs (GlobeNewswire)
Apr-13-26 06:57PM	Biomerica Reports Third Quarter Fiscal 2026 Financial Results (GlobeNewswire)
Mar-18-26 08:19AM	Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect) from One of the Largest Clinical Laboratory Chains in Europe (GlobeNewswire)
Mar-05-26 08:19AM	Biomerica Receives MHRA Registration for hp+detect, Allowing Commercial Sales in Great Britain (GlobeNewswire)
Feb-26-26 08:19AM	Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods IBS Therapy (GlobeNewswire) -5.09%
Feb-18-26 08:19AM	Vietnam Approves Biomerica's EZ Detect for Nationwide Distribution (GlobeNewswire)
Jan-14-26 05:17PM	Biomerica Reports Second Quarter Fiscal 2026 Financial Results (GlobeNewswire)
Dec-23-25 08:19AM	Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods IBS Test (GlobeNewswire) +10.55%
Dec-11-25 08:08AM	Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio (GlobeNewswire)
Nov-25-25 08:19AM	Biomerica's inFoods IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS (GlobeNewswire)
08:19AM	Loading…
Nov-06-25 08:19AM	Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand (GlobeNewswire)
Oct-16-25 08:19AM	Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica's inFoods IBS Test in the U.S. (GlobeNewswire) +5.24%
Oct-15-25 09:27AM	Biomerica Reports First Quarter Fiscal 2026 Financial Results (GlobeNewswire)
Oct-08-25 08:19AM	Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors (GlobeNewswire)
Sep-09-25 08:08AM	Biomerica Launches AI-Backed inFoods IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes (GlobeNewswire)
Sep-03-25 08:19AM	United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel Kidney Test for Home Use (GlobeNewswire) -5.00%
Aug-29-25 05:12PM	Biomerica Reports Fiscal 2025 Year End Results (GlobeNewswire)
Aug-18-25 05:07AM	Biomerica receives approval in UAE for at-home ulcer test (Medical Device Network)
Aug-14-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +15.84%
08:19AM	United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel Ulcer Test for Home Use (GlobeNewswire)
Jul-02-25 08:08AM	InFoods IBS receives CPT Proprietary Laboratory Analysis (PLA) Code (GlobeNewswire)
Jun-26-25 08:19AM	Clinical Diagnostics Industry Leader Scott Madel Joins Biomerica's Team as Chief Commercial Officer (GlobeNewswire)
Jun-06-25 09:30AM	Biomerica Appoints Eric B. Chin to Board of Directors and Audit Committee Chair (GlobeNewswire)
Jun-05-25 08:19AM	Biomerica's inFoods IBS Clinical Study Results Published in June Issue of Gastroenterology (GlobeNewswire)
May-22-25 08:19AM	Biomerica Reports Real-World Data Showing 49% Reduction in IBS Symptoms with inFoods IBS using a First of Its Kind Real-Time IBS Patient Feedback System (GlobeNewswire)
08:19AM	Loading…
May-07-25 08:19AM	PLA Code Application Filed for inFoods IBS Test - A Key Step Toward Reimbursement (GlobeNewswire) +5.26%
Apr-23-25 08:19AM	United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel Ulcer Test for Detection of H. pylori Infection (GlobeNewswire) +9.25%
Apr-21-25 09:02AM	Biomericas kidney disease test gains approval for sale in UAE (Medical Device Network)
Apr-17-25 08:19AM	United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel Kidney Disease Test for Early Detection of Kidney Damage (GlobeNewswire) +14.28%
Apr-16-25 09:00AM	Biomerica Announces Reverse Stock Split (GlobeNewswire) -26.29%
Apr-15-25 08:19AM	Biomerica Reports Third Quarter Fiscal 2025 Financial Results (GlobeNewswire)
Feb-27-25 05:18AM	Biomericas tests for IBD conditions gain CE-marking under EUs IVDR (Medical Device Network)
Feb-26-25 08:19AM	Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn's Disease and Ulcerative Colitis (GlobeNewswire) +9.39%
Feb-19-25 08:19AM	Biomerica's inFoods IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal (GlobeNewswire) -8.46%
Jan-17-25 10:48AM	Biomericas prostate cancer detection test gains approval from MOHAP (Medical Device Network) -9.35%
Jan-16-25 08:19AM	United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel PSA Screening Test to Detect an Early Sign of Prostate Cancer (GlobeNewswire) +101.71%
Jan-15-25 08:19AM	Biomerica Reports Second Quarter Fiscal 2025 Financial Results (GlobeNewswire) +6.84%
Nov-21-24 08:19AM	Biomerica Secures Three Key International Patents for inFoods Technology to Address GERD, Crohn's Disease, and Ulcerative Colitis (GlobeNewswire)
Nov-07-24 09:09AM	Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements (GlobeNewswire) +6.11%
Oct-30-24 08:19AM	Biomerica Announces Direct-to-Consumer Availability of inFoods IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain (GlobeNewswire) +18.75%
Oct-16-24 09:00AM	Biomerica Reports First Quarter Fiscal 2025 Financial Results (GlobeNewswire) +9.00%
Sep-04-24 08:19AM	The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer (GlobeNewswire) -11.67%
Aug-29-24 09:00AM	Biomerica Reports Fiscal 2024 Year End Results (GlobeNewswire)
Jul-16-24 07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jul-01-24 07:47AM	Biomerica Launches At-Home Sample Collection for inFoods IBS, Significantly Expanding Access for Millions of IBS Sufferers (GlobeNewswire)
May-13-24 08:19AM	Biomerica Announces inFoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 (GlobeNewswire)
Apr-29-24 11:33AM	Biomerica Enters Distribution Deal to Provide Home Screening Tests in UAE (MT Newswires) -19.95%
08:19AM	Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement (GlobeNewswire)
Apr-15-24 07:47AM	Biomerica provides update on inFoods IBS expansion (GlobeNewswire) -7.00%
Apr-12-24 10:52PM	BMRA Stock Earnings: Biomerica Reported Results for Q3 2024 (InvestorPlace)
07:23PM	Biomerica Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Mar-28-24 08:19AM	Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference (GlobeNewswire) -6.52%
Feb-21-24 08:19AM	Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board (GlobeNewswire) +5.37%
Jan-23-24 08:19AM	Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica (GlobeNewswire) +6.59%
Jan-16-24 02:51PM	BMRA Stock Earnings: Biomerica Reported Results for Q2 2024 (InvestorPlace)
08:19AM	Biomerica Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Dec-20-23 08:30AM	Joshua S. Horowitz Elected Chairman of the Board of Directors of BK Technologies (ACCESSWIRE)
Dec-18-23 07:47AM	Biomerica Received US FDA 510(k) Clearance for Their Hp Detect ELISA Test Product Designed to Detect the Presence of the H. pylori Bacteria That infects Approximately 35% of the U.S. Population (GlobeNewswire) +66.67%
Nov-10-23 08:19AM	Biomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16 (GlobeNewswire)
Nov-08-23 08:19AM	Biomerica Expands inFoods IBS Reach with Addition of Several New GI Groups (GlobeNewswire) +11.11%
Oct-13-23 01:10PM	REPEAT - Biomerica Reports First Quarter 2024 Financial Results (GlobeNewswire)
06:39AM	Biomerica Reports First Quarter 2024 Financial Results (GlobeNewswire)
Sep-26-23 08:19AM	Dubai Government Grants Insurance Reimbursement for Biomericas EZ Detect Colorectal Disease Screening Test (GlobeNewswire) -10.66%
Sep-22-23 03:05PM	Maxim Group LLC to Host the Virtual Tech Conference Series: Emerging Growth in A.I., on Tuesday, September 26th & Wednesday, September 27th at 8:00 A.M. ET. (GlobeNewswire)
Aug-28-23 08:19AM	Diagnostics Industry Leader Jack Kenny Joins Biomericas Board of Directors (GlobeNewswire)
Aug-25-23 05:00PM	Biomerica Reports Fiscal 2023 Year End Results (GlobeNewswire)
Aug-03-23 08:19AM	CVS Health to Begin Nationwide In-Store Sales of Biomericas EZ Detect Colorectal Disease Screening Test (GlobeNewswire) +13.01%
Jun-21-23 08:19AM	Biomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in Patients (GlobeNewswire)
May-18-23 08:19AM	inFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection Technology (GlobeNewswire) +15.00%
Apr-17-23 07:47AM	Biomericas inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS). (GlobeNewswire)
Apr-14-23 04:48PM	Biomerica Reports Q3 Fiscal 2023 Results (GlobeNewswire)
Mar-08-23 08:19AM	Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed (GlobeNewswire)
Mar-07-23 04:39PM	Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Mar-03-23 07:30AM	Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.06%
Mar-02-23 05:15PM	Biomerica Announces Proposed Underwritten Public Offering of Common Stock (GlobeNewswire)
Feb-20-23 05:57AM	We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate (Simply Wall St.)
Jan-23-23 06:00AM	Barnwell Industries, Inc. Reaches Cooperation and Support Agreement With its Largest Stockholders (GlobeNewswire)
Jan-13-23 06:39PM	Biomerica Reports Financial Results for Fiscal 2023 Second Quarter Ended November 30, 2022 (GlobeNewswire)
Jan-10-23 08:19AM	Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Companys Scientific Advisory Board (GlobeNewswire)
Dec-08-22 08:19AM	Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE (GlobeNewswire)
Dec-01-22 05:12AM	We Think Shareholders May Consider Being More Generous With Biomerica, Inc.'s (NASDAQ:BMRA) CEO Compensation Package (Simply Wall St.) +6.32%
Nov-02-22 08:19AM	Biomerica InFoods® IBS Data Presented at the 2022 American College of Gastroenterology (ACG) Annual Scientific Meeting (GlobeNewswire)
Oct-14-22 10:24AM	Walmart Expands Sales Of Biomerica's Aware Breast Self Exam To 2400 Stores (Benzinga) -6.57%
09:46AM	Biomerica stock leaps as Walmart expands sales of Aware Breast Self Exam to its stores (MarketWatch)
09:18AM	Walmart to Expand Sales of Biomericas Aware® Breast Self Exam; Product will now be available in over 2400 Walmart stores (GlobeNewswire)
Oct-13-22 04:50PM	Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022 (GlobeNewswire)
Oct-11-22 06:25AM	Those who invested in Biomerica (NASDAQ:BMRA) five years ago are up 39% (Simply Wall St.)
Sep-29-22 08:19AM	Biomericas Aware® Breast Self Exam and EZ Detect Colon Disease Test Now Available on Amazon and Fulfilled by Amazon (GlobeNewswire)
Aug-31-22 06:25AM	We're Interested To See How Biomerica (NASDAQ:BMRA) Uses Its Cash Hoard To Grow (Simply Wall St.)
Aug-30-22 08:19AM	Biomerica Plans Launch of InFoods® IBS Test; Names Robert Carlson as Chief Commercial Officer (GlobeNewswire)
Aug-29-22 04:41PM	Biomerica Reports Fiscal 2022 Year End Results (GlobeNewswire)
Jul-14-22 11:50AM	Walmart to Start Selling Biomerica's Aware Breast Self Exam Devices (Benzinga) +8.00%
08:19AM	Walmart to Begin Selling Biomericas Aware® Breast Self Exam (GlobeNewswire)
Jun-23-22 08:19AM	Biomerica to Participate at BTIG Biotech Conference (GlobeNewswire)
May-16-22 01:20PM	36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022 (ACCESSWIRE) -6.40%

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, North America, Asia, South America, and Middle East. The company was founded in September 1971 and is headquartered in Irvine, CA.

CEO & DirectorMr. Zackary S. Irani

Executive Vice-Chairman of the Board & Corporate SecretaryMr. Allen C. Barbieri

Principal Accounting OfficerMr. Gary Lu CPA

Director of Manufacturing & Technical OperationsMs. Lucy Liu Ph.D.

Chief Commercial OfficerMr. Scott Madel

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gary M. Huff	Director	Aug 20 '26	Buy	1.60	31,250	50,000	51,250	Aug 27 05:27 PM
MOATAZEDI DAVID	Director	Aug 26 '26	Buy	1.60	10,000	16,000	40,625	Aug 27 05:26 PM
Chin Eric	Director	Aug 26 '26	Buy	1.60	6,250	10,000	38,750	Aug 27 05:26 PM
BARBIERI ALLEN	Executive Vice Chairman	Aug 26 '26	Buy	1.60	20,000	32,000	73,542	Aug 27 05:24 PM
Irani Zackary S.	Chief Executive Officer	Aug 26 '26	Buy	1.60	31,250	50,000	242,570	Aug 27 05:23 PM

Open in Screener

EOLS

Evolus Inc

9.06

Sep 02 • 3:59 PM ET -0.02 (-0.22%)

9.10

Aftermarket • 7:30 PM ET +0.04 (0.44%)

Healthcare Drug Manufacturers - Specialty & Generic USA Small NASD

Peers: INMD ALGN BLCO GMED ABT BSX EW MDT AXSM GKOS

| Held by: IWM VTI IWO VXF XPH SCHA IHE VTWO IWC GSSC

Index	RUT
Market Cap	598.42M
Enterprise Value	718.05M
Income	-34.33M
Sales	316.49M
Book/sh	-0.47
Cash/sh	0.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	334
IPO	Feb 08, 2018

P/E	-
Forward P/E	36.45
PEG	-
P/S	1.89
P/B	-
P/C	13.25
P/FCF	-
EV/EBITDA	-
EV/Sales	2.27
Quick Ratio	1.28
Current Ratio	1.70
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.53
EPS next Y	0.25
EPS next Q	-0.07
EPS this Y	90.44%
EPS next Y	691.84%
EPS next 5Y	-
EPS past 3/5Y	15.49% 30.19%
Sales past 3/5Y	25.98% 39.36%
EPS Y/Y TTM	45.83%
Sales Y/Y TTM	13.87%
EPS Q/Q	54.03%
Sales Q/Q	21.18%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	122.22% 3.11%

Insider Own	12.36%
Insider Trans	-1.96%
Inst Own	69.40%
Inst Trans	6.32%
ROA	-14.40%
ROE	-18729.61%
ROIC	-26.14%
Gross Margin	64.95%
Oper. Margin	-6.51%
Profit Margin	-10.85%
SMA20	7.84%
SMA50	26.15%
SMA200	50.13%
Trades

Shs Outstand	66.01M
Shs Float	57.89M
Short Float	10.11%
Short Ratio	6.56
Short Interest	5.85M
52W High	9.15 -0.98%
52W Low	3.86 134.72%
Volatility	3.61% 5.43%
ATR (14)	0.38
RSI (14)	70.52
Beta	1.32
Rel Volume	0.87
Avg Volume	891.98K
Volume	773,978

Perf Week	3.19%
Perf Month	48.04%
Perf Quarter	50.25%
Perf Half Y	62.08%
Perf YTD	36.24%
Perf Year	20.80%
Perf 3Y	-8.58%
Perf 5Y	-13.71%
Perf 10Y	-
Recom	1.29
Target Price	15.00
Prev Close	9.08
Price	9.06
Change %	-0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-25	Downgrade	Needham	Buy → Hold
Apr-17-25	Initiated	BTIG Research	Buy	$21
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $16
Jun-23-22	Initiated	Needham	Buy	$18
May-12-22	Upgrade	Barclays	Underweight → Equal Weight	$8 → $10
Jan-20-22	Upgrade	Truist	Hold → Buy	$11
May-06-21	Upgrade	Mizuho	Neutral → Buy	$15
Apr-08-21	Reiterated	H.C. Wainwright	Buy	$20 → $22
Feb-24-21	Downgrade	Truist	Buy → Hold	$12
Jul-07-20	Downgrade	Mizuho	Buy → Neutral	$8 → $3
Feb-06-20	Resumed	Mizuho	Buy
Nov-26-19	Initiated	SVB Leerink	Outperform	$25
Sep-05-19	Resumed	Mizuho	Buy	$30
Jun-28-19	Initiated	Wells Fargo	Market Perform	$16
Jun-11-19	Initiated	Barclays	Underweight	$13
Mar-20-19	Initiated	SunTrust	Buy	$30
Feb-14-19	Initiated	H.C. Wainwright	Buy	$37
Jan-29-19	Initiated	Stifel	Buy	$27

Show Previous Ratings

Sep-01-26 11:37AM	A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture (PR Newswire)
Aug-06-26 01:07AM	Evolus Inc (EOLS) (Q2 2026) Earnings Call Highlights: Revenue Surges 21% and Adjusted EBITDA ... (GuruFocus.com) +19.90%
Aug-05-26 04:05PM	Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook (Business Wire)
Aug-04-26 08:30AM	Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme in Canada, Australia, and New Zealand (Business Wire)
Jul-22-26 08:30AM	Evolus to Report Second Quarter Financial Results on August 5, 2026 (Business Wire)
04:05PM	Loading…
Jul-10-26 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-26 08:16AM	One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics (PR Newswire)
Jul-08-26 09:00AM	Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo in the United States, Expanding Its Injectable Portfolio into Skin Quality (Business Wire)
May-22-26 10:31AM	Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It (PR Newswire) -5.58%
May-19-26 08:30AM	Evolus to Participate in The Jefferies Global Healthcare Conference (Business Wire)
May-11-26 08:30AM	Evolus Announces Commercial Launch of Estyme Injectable Hyaluronic Acid Gels in Europe (Business Wire)
May-04-26 08:23PM	Evolus, Inc. Q1 2026 Earnings Call Summary (Moby) +14.16%
04:05PM	Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook (Business Wire)
Apr-14-26 08:30AM	Evolus to Report First Quarter Financial Results on May 4, 2026 (Business Wire)
Apr-07-26 03:35PM	Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization (Exec Edge)
08:00AM	Loading…
Mar-31-26 08:00AM	Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference (Business Wire)
Mar-20-26 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-04-26 08:30AM	Evolus, Inc. Q4 2025 Earnings Call Summary (Moby) +35.35%
12:01AM	Evolus Inc (EOLS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com)
Mar-03-26 07:02PM	Evolus Q4 Earnings Call Highlights (MarketBeat)
06:05PM	Evolus, Inc. (EOLS) Matches Q4 Earnings Estimates (Zacks)
04:05PM	Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026 (Business Wire)
Feb-25-26 07:25PM	Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
08:00AM	Evolus to Participate in The Leerink Partners Global Healthcare Conference (Business Wire)
Feb-24-26 10:00AM	Evolus, Inc. (EOLS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-17-26 08:00AM	Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026 (Business Wire)
Feb-13-26 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-09-26 02:13PM	Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating (Insider Monkey) -5.78%
Feb-04-26 07:40AM	Boston Scientific (BSX) Beats Q4 Earnings and Revenue Estimates (Zacks)
Jan-09-26 08:30AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue (Business Wire)
11:10PM	Loading…
Dec-15-25 11:10PM	Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics (Insider Monkey)
Nov-14-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-25 12:04AM	Evolus Inc (EOLS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com) +5.43%
Nov-05-25 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +6.24%
04:05PM	Evolus Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-30-25 10:00AM	Earnings Preview: Prestige Consumer Healthcare (PBH) Q2 Earnings Expected to Decline (Zacks)
Oct-29-25 10:00AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-28-25 08:00AM	Evolus to Participate in 2025 Stifel Healthcare Conference (Business Wire)
Oct-22-25 08:00AM	Evolus to Report Third Quarter Financial Results on November 5, 2025 (Business Wire)
Oct-10-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-22-25 09:03AM	Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse Filler Launch (PR Newswire)
Sep-12-25 05:30PM	Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.79%
Sep-08-25 08:30AM	Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer (Business Wire)
Aug-25-25 08:00AM	Evolus Announces Positive Data From Pivotal Trial for Evolysse Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp (Business Wire)
Aug-20-25 08:00AM	Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse Sculpt Injectable Hyaluronic Acid Gel Product (Business Wire)
Aug-08-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-05-25 06:30PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -28.51%
04:05PM	Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Jul-31-25 10:00AM	Analysts Estimate Haemonetics (HAE) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:05AM	Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau as a Top Performer Among Leading Neurotoxins (Business Wire)
Jul-29-25 10:00AM	Earnings Preview: Evolus, Inc. (EOLS) Q2 Earnings Expected to Decline (Zacks)
Jul-22-25 08:05AM	Evolus to Report Second Quarter Financial Results on August 5, 2025 (Business Wire)
Jul-11-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-25 08:00AM	Evolus Expands Global Footprint with Introduction of Nuceiva (botulinum toxin type A) in France (Business Wire)
Jun-13-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-10-25 08:00AM	Evolysse Recognized in 2025 Shape Skin Awards (Business Wire)
May-27-25 04:15PM	Evolus Announces Departure of its Chief Financial Officer (Business Wire) -5.20%
May-22-25 08:00AM	Evolus Announces Publication of U.S. Pivotal Study for Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels (Business Wire)
May-16-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-13-25 09:51AM	Evolus, Inc. (EOLS): A Bull Case Theory (Insider Monkey)
May-08-25 09:47AM	Q1 2025 Evolus Inc Earnings Call (Thomson Reuters StreetEvents) -14.20%
03:28AM	Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com)
May-07-25 07:14PM	Evolus projects $345M-$355M revenue for 2025 with new product launches (Seeking Alpha)
07:13PM	Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:55PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports First Quarter 2025 Results (Business Wire)
May-05-25 04:05PM	Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility (Business Wire)
May-01-25 07:30AM	SNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-23-25 08:00AM	Evolus to Report First Quarter Financial Results on May 7, 2025 (Business Wire) +7.36%
Apr-22-25 07:10PM	Evolus: Two-Product Aesthetics Company With A Competitive Edge (Seeking Alpha)
Apr-18-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-16-25 08:00AM	Evolus Announces Commercial Launch of Evolysse (Business Wire)
Apr-15-25 08:00AM	Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse Injectable Hyaluronic Acid Gels (Business Wire)
Mar-25-25 08:00AM	Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference (Business Wire)
Mar-21-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-10-25 04:53PM	Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas (Motley Fool) -6.63%
Mar-05-25 07:13AM	Q4 2024 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com)
Mar-04-25 05:25PM	Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates (Zacks)
04:05PM	Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance (Business Wire)
Mar-02-25 06:08PM	Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-27-25 08:00AM	Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences (Business Wire)
Feb-20-25 08:00AM	Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit (Business Wire)
Feb-18-25 08:00AM	Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 (Business Wire)
Feb-14-25 08:53AM	Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Feb-13-25 01:30PM	Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels (Business Wire) +5.47%
Feb-07-25 07:09PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-22-25 07:46AM	Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? (Zacks)
Jan-21-25 04:04PM	Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere Here's Why (Investor's Business Daily) +28.26%
08:00AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Companys Guidance (Business Wire)
Jan-17-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 09:55AM	Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-14-24 09:35AM	Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) (Zacks)
Nov-07-24 06:00AM	Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges (GuruFocus.com) -14.99%
Nov-06-24 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports Third Quarter 2024 Results (Business Wire)
Nov-01-24 08:00AM	Evolus to Participate in Stifel 2024 Healthcare Conference (Business Wire)
Oct-31-24 02:02PM	Evolus Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation (Business Wire)

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

PresidentMr. David Moatazedi

Chief Financial OfficerMs. Tatjana Mitchell

Dip.SportMedDr. Rui Avelar C.CFP

Head of Global Investor Relations & Corporate CommunicationsMr. Nareg Sagherian

Senior Vice President of SalesMr. Kurt Knab

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DAVID MOATAZEDI	Officer	Sep 02 '26	Proposed Sale	9.04	105,108	950,019		Sep 02 04:55 PM
Avelar Rui	See Remarks	Mar 20 '26	Sale	4.75	3,119	14,815	427,423	Mar 20 07:19 PM
MOATAZEDI DAVID	See Remarks	Mar 20 '26	Sale	4.75	13,669	64,929	604,700	Mar 20 07:19 PM
MOATAZEDI DAVID	See Remarks	Mar 16 '26	Option Exercise	0.00	67,489	0	735,089	Mar 18 08:00 PM
MOATAZEDI DAVID	See Remarks	Mar 17 '26	Sale	4.89	116,720	570,562	618,369	Mar 18 08:00 PM
Avelar Rui	See Remarks	Mar 16 '26	Option Exercise	0.00	8,804	0	460,538	Mar 18 08:00 PM
Avelar Rui	See Remarks	Mar 17 '26	Sale	4.89	29,996	146,629	430,542	Mar 18 08:00 PM
MOATAZEDI DAVID	See Remarks	Dec 22 '25	Sale	7.15	10,539	75,361	354,388	Dec 29 06:42 PM
Avelar Rui	See Remarks	Dec 22 '25	Sale	7.15	2,261	16,168	356,821	Dec 29 06:42 PM

BMRA

Biomerica Inc

EOLS

Evolus Inc

Upgrade your Finviz experience